Welcome to our dedicated page for roivw news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on roivw stock.
Riovant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of medicines that matter. The company's pipeline includes VTAMA®, a topical treatment for psoriasis and atopic dermatitis, IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor in autoimmune indications, and brepocitinib, a small molecule inhibitor for dermatomyositis and non-infectious uveitis. Through creating nimble subsidiaries, Roivant aims to advance its therapies and technologies, while also nurturing discovery-stage companies and health tech startups.
Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a live conference call and webcast on November 13, 2023, to report its Q2 2023 financial results and provide a business update. The conference call will be accessible via phone registration and the webcast will be available on the Roivant website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
-
Rhea-AI Summary
Roche has entered into a definitive agreement with Roivant to acquire Telavant Holdings, gaining the rights to develop and commercialize RVT-3101, a novel TL1A directed antibody for the treatment of inflammatory bowel disease. Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. The agreement also includes an option for a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.02%
Tags
-
Rhea-AI Summary
IMVT-1402 subcutaneous doses showed dose-dependent reductions in IgG with no adverse effects on serum albumin or LDL-C levels. Initial data supports IMVT-1402 as a potential best-in-class FcRn inhibitor. Mean total IgG reduction from baseline in the 300 mg MAD cohort was 63%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.55%
Tags
Rhea-AI Summary
Roivant completes redemption of outstanding warrants at $0.10 per warrant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
-
Rhea-AI Summary
Roivant announces the Redemption Fair Market Value for its outstanding public and private placement warrants. The Redemption Fair Market Value is $11.35 per warrant. Holders who exercise their warrants on a cashless basis will receive approximately 0.2495 common shares per warrant. The redemption price for the warrants is $0.10 per warrant. The warrants will cease trading on the redemption date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a conference call on August 14, 2023, to report Q2 2023 financial results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
-
Rhea-AI Summary
Telavant initiates Phase 2 clinical trial of RVT-3101 for Crohn's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.27%
Tags
FAQ
What is Roivant Sciences Ltd. focused on?
Roivant Sciences Ltd. is focused on accelerating the development and commercialization of medicines that matter, with a pipeline of innovative treatments for various conditions.
What are some products in Roivant Sciences Ltd.'s pipeline?
Roivant Sciences Ltd.'s pipeline includes VTAMA®, IMVT-1402, batoclimab, and brepocitinib, targeting autoimmune diseases and other conditions.
How does Roivant Sciences Ltd. advance its pipeline?
Roivant Sciences Ltd. advances its pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize its medicines and technologies.
What additional initiatives does Roivant Sciences Ltd. undertake?
In addition to therapeutics, Roivant Sciences Ltd. incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business.
What is the significance of Roivant Sciences Ltd.'s latest achievements?
Roivant Sciences Ltd. has recently achieved positive results in Phase 2 studies, such as the NEPTUNE study, showing the efficacy of brepocitinib in non-anterior non-infectious uveitis, indicating potential transformative benefits for patients.
roivw